Introduction: The definition of acute lower respiratory tract infection (LRTI) includes any infection involving the respiratory tract below the level of the larynx. In children, the most common acute LRTIs, and those with the greatest clinical relevance, are community-acquired pneumonia (CAP), bronchiolitis, bronchitis and tuberculosis (TB). The clinical relevance of LRTIs implies that they must be addressed with the most effective therapy. Antibiotics and antivirals play an essential role in this regard. Areas covered: In this paper, the most recent advances in the drug treatment of LRTIs in children are discussed. Expert opinion: Although LRTIs are extremely common and one of the most important causes of hospitalization and death in children, anti-infective therapy for these diseases remains unsatisfactory. For CAP and BR, the most important problem is the overuse and misuse of antibiotics; for BCL, the lack of drugs with demonstrated efficacy, safety and tolerability; for TB, the poor knowledge on the true efficacy and safety of the new drugs specifically planned to overcome the problem of MDR M. tuberculosis strains. There is still a long way to go for the therapy of pediatric LRTIs to be considered satisfactory.
How does one choose the appropriate pharmacotherapy for children with lower respiratory tract infections? / Esposito, S.; Bianchini, S.; Argentiero, A.; Neglia, C.; Principi, N.. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 21:14(2020), pp. 1739-1747. [10.1080/14656566.2020.1781091]
|Appare nelle tipologie:||1.1 Articolo su rivista|